| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2873194 | The Annals of Thoracic Surgery | 2015 | 7 Pages |
Abstract
The rates of neoadjuvant CRT toxicity and postoperative complications were acceptable, and the complete resection rate and survival data were favorable. This regimen is promising as neoadjuvant CRT for esophageal cancer and very useful as an alternative regimen for treating patients with esophageal cancer who cannot tolerate cisplatin.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Yoichi MD, PhD, Jun MD, PhD, Manabu MD, PhD, Yuji MD, PhD, Masahiro MD, PhD, Yasushi MD, PhD, Morihito MD, PhD,